BioMarin Pharmaceutical (BMRN) is back in focus after the company reported Q2 revenue that topped analyst expectations by 6.5% and issued full year EPS guidance above prior estimates, with the stock up 13% since that report.

Over the past few months, BioMarin Pharmaceutical has seen stronger momentum, with a 30 day share price return of 15.89% and a 90 day share price return of 25.12%, while the 3 year total shareholder return is still down 27.72%. This shows that recent enthusiasm following earnings and the Alesta and Amicus deals is developing from a lower long term base.

If BioMarin’s recent moves in rare diseases have your attention, it could be a good moment to look at other healthcare companies using AI to reshape treatment options through the 40 healthcare AI stocks.

After a 13% jump on earnings and deal news, BioMarin Pharmaceutical is no longer priced like a recovery story from its weaker three year return. Are investors still underestimating it, or has most of the re rating already happened?

Most Popular Narrative: 23% Undervalued

BioMarin Pharmaceutical's most followed narrative points to a fair value of $87.85 against the last close at $67.68, which frames the recent rebound as only part of the story.

Strong year over year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top line revenue growth.

BioMarin raised 2026 total revenue guidance to a range of US$3.825b to US$3.925b, compared with prior guidance of US$3.325b to US$3.425b. Read the complete narrative.

If you want to see what is really backing that $87.85 fair value, the narrative leans heavily on sharp earnings expansion, richer margins and a future earnings multiple that looks very different from today. The interesting part is how those three ingredients are combined, and which assumptions do most of the heavy lifting.

Result: Fair Value of $87.85 (UNDERVALUED)

However, BioMarin Pharmaceutical still faces meaningful risk from intensifying rare disease competition and higher R&D and commercial costs that could pressure margins and earnings expectations.

Next Steps

With both clear risks and meaningful upside arguments on the table for BioMarin Pharmaceutical, it makes sense to move quickly and pressure test the details yourself. To weigh both sides in one place and decide where you stand, review the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond BioMarin Pharmaceutical?

If you are serious about building a stronger portfolio, do not stop with BioMarin Pharmaceutical. Use the Simply Wall Street Screener to surface fresh opportunities fast.

• Target reliable cash generators and resilient balance sheets by checking stocks in the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for potential mispricings by scanning companies in the 50 high quality undervalued stocks.
• Spot future market leaders early by reviewing the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.